Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis
Caihong Liu, Yingying Yang, Jinglei Ren, Yongxiu Huang, Wei Wei, Xu Li, Fang Wang, Xue Tang, Ping Fu, Ling Zhang, Yuliang Zhao · 2025
Read Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis by Caihong Liu, Yingying Yang, Jinglei Ren, Yongxiu Huang, Wei Wei, Xu Li, Fang Wang, Xue Tang, Ping Fu, Ling Zhang, Yuliang Zhao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12896118.txt.
Description
Caihong Liu and co-authors give a set review of nafamostat mesilate, used to stop blood from clotting while blood is cleaned. Their 2025 meta-analysis sets it next to heparin, next to citrate, and next to plans that use no drug to stop clotting.
Sixteen studies took part, with over four thousand people in all. They covered renal replacement therapy and extracorporeal membrane oxygenation. Nafamostat showed a risk of bleeding that was far lower than the drugs it was set next to. Its risk ratio was close to one half. How long filters lasted, and other results, were also set side by side. Checks were split by the type of drug and by the way the blood was cleaned. The team gauged the quality of the studies, how firm the results were, and bias in which studies came out.
Catalog record
| CREATOR | Caihong Liu, Yingying Yang, Jinglei Ren, Yongxiu Huang, Wei Wei, Xu Li, Fang Wang, Xue Tang, Ping Fu, Ling Zhang, Yuliang Zhao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |